Phase 2 Schizophrenia Trial, Recruiting NCT03794076 Sponsor: Vishwajit Nimgaonkar, MD PhD Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT03794076
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to give written agreement to take part in the trial.
  • You are between 18 and 60 years old (any gender).
  • You have been diagnosed with schizophrenia or schizoaffective disorder according to standard diagnostic guidelines (DSM-5).
  • You have been taking the same antipsychotic medication for at least 60 days, at a stable dose for more than 1 month, and are able to continue taking it throughout the study.
  • Your symptoms score at a certain level on a standard rating scale, including at least one notable "positive" symptom (such as hallucinations or delusions) (confirm with trial site).
  • People who have had psychosis for less than 7 years are preferred for this trial.

Who may not be able to join:

  • You have used illegal drugs in the last 30 days, or have had a drug dependency in the last 6 months (note: people receiving methadone treatment for opioid withdrawal may still be eligible).
  • You have a current or past medical or neurological condition that could cause an unstable health course (people with epilepsy that has been well-controlled on medication for at least 6 months may still be eligible).
  • You are pregnant.
  • You have a history of immune system disorders, HIV infection, or are currently taking medications that affect the immune system (such as steroids).
  • You have previously received or are currently receiving treatment with CGY, or have had an allergic reaction to CGY in the past (confirm with trial site).
  • You have an intellectual disability as defined by standard diagnostic guidelines (DSM-5).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Vishwajit L. Nimgaonkar, M.D., Ph.D., University of Pittsburgh

Phone: (412) 246-6353

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Vishwajit Nimgaonkar, MD PhD
Registry
ClinicalTrials.gov
Start date
1 April 2019
Est. completion
1 January 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Improvement in positive symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov